That Ann from TSM looks alright. Fin-tech company and the profit guidance update estimates a 42% (averaged) increase on their NPAT. Up from 3.5Mil last year to approximately 4.5 - 5.5Mil this year. MC= 36.8Mil.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
